LEE011 Meets Primary Endpoint, Improves PFS in Phase III Trial

Perjeta biosimilar safe and effective for breast cancer in phase III trial

The phase III comparative clinical trial for the investigational Perjeta (pertuzumab) biosimilar HLX11 met the primary endpoint of total pathological complete response rate.

October 04, 2024

Vol.50 No.37

Regulatory News

New FDA mandate to tell patients whether their breasts are “dense” or “not dense” baffles doctors
Problem: “Breast density is in the eye of the mammographer”

Collage art of mammograms of dense breastsIllustrator: Cyrus FineganWhile breast cancer experts are anything but clear on what the words “dense breasts” signify in the clinic, or for that matter, in the English language, FDA appears to be less perplexed.

September 27, 2024

Vol.50 No.36

By Claire Marie Porter

Cancer History Project Guest Editorial

How First Lady Betty Ford and surgeon Bernie Fisher revolutionized America’s attitude toward breast cancer

It is rare that an ABC Movie of the Week endures. Buzz Kulik’s 1971 “Brian’s Song” is a notable exception.

Jose and Irma Russo— husband and wife trailblazers in breast cancer research

Jose and Irma Russo dedicated their careers to investigating breast cancer, its causes, and potential prevention measures.

September 27, 2024

Vol.50 No.36

In Brief

UMich Rogel Cancer Center receives $25M from Weiser Charitable Foundation

Drs. Melissa Pilewskie (left) and Monika Burness, co-leads of the Weiser Family Center for Breast CancerPhoto credit: Michigan MedicineThe Weiser Charitable Foundation donated $25 million to support the establishment the Weiser Family Center for Breast Cancer at the University of Michigan Health Rogel Cancer Center.

September 27, 2024

Vol.50 No.36

Clinical Roundup

Accelerated partial-breast irradiation is not statistically equivalent to whole-breast irradiation in local tumor control, NRG oncology trial shows

The NRG Oncology NSABP B-39/RTOG 0413 clinical trial compared whole-breast irradiation to accelerated partial-breast irradiation and determined that APBI was not statistically equivalent to WBI in local tumor control. The secondary outcome for the trial was quality-of-life.

September 20, 2024

Vol.50 No.35

LEE011 Meets Primary Endpoint, Improves PFS in Phase III Trial

YOU MAY BE INTERESTED IN

Perjeta biosimilar safe and effective for breast cancer in phase III trial

New FDA mandate to tell patients whether their breasts are “dense” or “not dense” baffles doctors
Problem: “Breast density is in the eye of the mammographer”

How First Lady Betty Ford and surgeon Bernie Fisher revolutionized America’s attitude toward breast cancer

Jose and Irma Russo— husband and wife trailblazers in breast cancer research

UMich Rogel Cancer Center receives $25M from Weiser Charitable Foundation

Accelerated partial-breast irradiation is not statistically equivalent to whole-breast irradiation in local tumor control, NRG oncology trial shows

Renew today!

Subscriber content

Can you spare 10 minutes to complete a survey?

Login

LEE011 Meets Primary Endpoint, Improves PFS in Phase III Trial

YOU MAY BE INTERESTED IN

Perjeta biosimilar safe and effective for breast cancer in phase III trial

New FDA mandate to tell patients whether their breasts are “dense” or “not dense” baffles doctorsProblem: “Breast density is in the eye of the mammographer”

How First Lady Betty Ford and surgeon Bernie Fisher revolutionized America’s attitude toward breast cancer

Jose and Irma Russo— husband and wife trailblazers in breast cancer research

UMich Rogel Cancer Center receives $25M from Weiser Charitable Foundation

Accelerated partial-breast irradiation is not statistically equivalent to whole-breast irradiation in local tumor control, NRG oncology trial shows

Can you spare 10 minutes to complete a survey?

Login

New FDA mandate to tell patients whether their breasts are “dense” or “not dense” baffles doctors
Problem: “Breast density is in the eye of the mammographer”